News summary

New Treatment Strategy for Down Syndrome Shows Promise in Phase 2 Clinical Trial

Source: PR Newswire • Published: 18 Nov 2026, 17:25

Summarized by Masters of Longevity from PR Newswire.

A phase 2 trial found tofacitinib reduced immune overactivity and improved skin conditions.

New Treatment Strategy for Down Syndrome Shows Promise in Phase 2 Clinical Trial
Key Takeaways
  • Tofacitinib reduced interferon-driven immune signaling in participants.
  • Tofacitinib improved hidradenitis suppurativa and alopecia areata scores.
  • Causal neurological benefits were not proven without placebo controls.
Read the full article at PR Newswire ↗

Continue exploring

Recommended MoL Picks

MoL PickReducing Inflammation from Ageing Cells: What a Mouse Study FoundResearchers reduced the inflammatory signals released by cells that had stopped dividing. Older mice also improved on some strength and frailty tests. Whether this approach could help people remains unknown.MoL PickWhat Changes in the Human Hippocampus with Age?A study of 40 postmortem brains maps a midlife shift in immune cells and a wider loss of cellular and genome organisation—but it does not show how to prevent cognitive decline.MoL PickCreatine and Cancer: Why New Mouse Studies Point in Opposite DirectionsCreatine strengthened antitumour immune cells in one mouse study—and promoted metastasis through platelets in another. The apparent contradiction reveals why neither result is a supplement recommendation.